The prognostic values of CA125, CA19.9, NSE, and SCC for stage I NSCLC are limited

Cancer Biomarkers

Volumn 10, Issue 3-4, 2011, Pages 155-162

  Ma, Shaohua ^a   Shen, Luyan ^a   Qian, Na ^a   Chen, Keneng ^a  

^a PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

Author keywords

Non small cell lung cancer; serum tumor markers; survival rate

Indexed keywords

CA 125 ANTIGEN; CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CYTOKERATIN 19 FRAGMENT; NEURON SPECIFIC ENOLASE; SQUAMOUS CELL CARCINOMA ANTIGEN;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURGERY; CANCER SURVIVAL; CHEMOLUMINESCENCE; DISEASE COURSE; ELECTROIMMUNOASSAY; FEMALE; HOSPITAL PATIENT; HUMAN; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; THORAX SURGERY;

ADULT; AGED; ANTIGENS, NEOPLASM; CA-125 ANTIGEN; CA-19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOASSAY; KAPLAN-MEIER ESTIMATE; KERATIN-19; LUNG NEOPLASMS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; NEOPLASM STAGING; OUTCOME ASSESSMENT (HEALTH CARE); PHOSPHOPYRUVATE HYDRATASE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; SERPINS; TUMOR MARKERS, BIOLOGICAL;

EID: 84862844389     PISSN: 15740153     EISSN: 18758592     Source Type: Journal    
DOI: 10.3233/CBM-2012-0246     Document Type: Article

References (27)

1. León-Atance P, Moreno-Mata N, González-Aragoneses F, et al. Multicenter Analysis of Survival and Prognostic Factors in Pathologic Stage I Non-Small-Cell Lung Cancer According to the New 2009 TNM Classification. Arch Bronconeumol. 2011; 47: 441-446. [PubMed: 21676516].
2. Kameyama K, Takahashi M, Ohata K, et al. Evaluation of the new TNM staging system proposed by the International Association for the Study of Lung Cancer at a single institution. J Thorac CardiovascSurg. 2009; 137: 1180-1184. [PubMed: 19379988].
3. Strauss GM, Herndon JE, Maddaus MA, et al. Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. J Clin Oncol. 2008; 26: 5043-5051. [PubMed: 18809614].
4. Harpole DH, Richards WG, Herndon JE, Suqarbaker DJ. Angiogenesis and molecular biologic substaging in patients with stage I non-small-cell lung cancer. Ann Thorac Surg. 1996; 61: 1470-1476. [PubMed: 8633961]. (Pubitemid 26150240)
5. Potti A, Mukherjee S, Petersen R, et al. Agenomic strategy to refine prognosis in early-stage non-small-cell lung cancer. N Engl J Med.2006;355: 570-580. [PubMed: 16899777]. (Pubitemid 44200650)
6. Okada M, NishioW, Sakamoto T, et al. Prognostic significance of perioperative serum carcinoembryonic antigen in non-small cell lung cancer: analysis of 1,000 consecutive resections for clinical stage I disease. Ann Thorac Surg. 2004; 78: 216-221. [PubMed: 15223432]. (Pubitemid 38833935)
7. Ballesta AM, Molina R, Filella X, Jo J, Giménez N. Carcinoembryonic antigen in staging and follow-up of patients with solid tumors. Tumour Biol. 1995; 16: 32-41. [PubMed: 7863220].
8. Stieber P, Hasholzner U, Bodenmüller H, et al. CYFRA 21-1. A new marker in lung cancer. Cancer. 1993; 72: 707-713. [PubMed: 7687515]. (Pubitemid 23215254)
9. EbertW, Hoppe M, Muley T, Drings P. Monitoring of therapy in inoperable lung cancer patients bymeasurement of CYFRA 21-1, TPA- TP CEA, and NSE. Anticancer Res. 1997; 17: 2875-2878. [PubMed: 9329552]. (Pubitemid 27434809)
10. Yagi H, Danno K, Maruguchi Y, Yamamoto M, Imamura S. Significance of squamous cell carcinoma (SCC)-related antigens in cutaneous SCC. A preliminary report. Arch Dermatol. 1987; 123: 902-906. [PubMed: 3606169]. (Pubitemid 17090479)
11. Herlyn M, Sears HF, Steplewski Z, Koprowski H. Monoclonal antibody detection of a circulating tumor-associated antigen. I. Presence of antigen in sera of patients with colorectal, gastric, and pancreatic carcinoma. J Clin Immunol. 1982; 2: 135-140. [PubMed: 7068815]. (Pubitemid 13227806)
12. Bast RC, Klug TL, St John E, et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl JMed. 1983; 309: 883-887. [PubMed: 6310399]. (Pubitemid 13014028)
13. Liang QL, Shi HZ, Qin XJ, Liang XD, Jiang J, Yang HB. Diagnostic accuracy of tumour markers for malignant pleural effusion: ameta-analysis. Thorax. 2008; 63: 35-41. [PubMed: 17573438].
14. Gube M, Taeger D,Weber DG, et al. Performance of biomarkers SMRP, CA125, and CYFRA 21-1as potential tumor markers for malignant mesothelioma and lung cancer in a cohort of workers formerly exposed to asbestos. Arch Toxicol. 2011; 85: 185-192. [PubMed: 20737138].
15. Molina R, Augé JM, Bosch X, et al. Usefulness of Serum Tumor Markers, Including Progastrin-Releasing Peptide, in Patients with Lung Cancer: Correlation with Histology. Tumour Biol. 2009; 30: 121-129. [PubMed: 19506400].
16. San Jose ME, Alvarez D, Valdes L, et al. Utility of tumour markers in the diagnosis of neoplastic pleural effusion. Clin. Chim. Acta. 1997; 265: 193-205. [PubMed:9385461]. (Pubitemid 27438278)
17. Matsuguma H, Nakahara R, Igarashi S, et al. Pathologic stage I non-small-cell lung cancer with high levels of preoperative serum carcinoembryonic antigen: Clinicopathologic characteristics and prognosis. J Thorac Cardiovasc Surg. 2008; 135: 44-49. [PubMed:18179917].
18. Muley T, Dienemann H, Ebert W. CYFRA 21-1 and CEA are independent prognostic factors in 153 operated stage I NSCLC patients. Anticancer Res. 2004; 24: 953-1956. [PubMed:15274383].
19. Suzuki H, Ishikawa S, Satoh H, et al. Preoperative CYFRA 21-1 levels as a prognostic factor in c-stage I non-small cell lung cancer. Eur J Cardiothorac Surg. 2007; 32: 648-652. [PubMed:17707694]. (Pubitemid 47362711)
20. Matsuoka K, Sumitomo S, Nakashima N, Nakajima D, Misaki. Prognostic value of carcinoembryonic antigen and CYFRA21-1 in patients with pathological stage I non-small cell lung cancer. Eur J Cardiothorac Surg. 2007; 32: 435-439. [PubMed:17611117]. (Pubitemid 47223713)
21. Mizuguchi S, Nishiyama N, Iwata T, et al. Serum Sialyl Lewis and cytokeratin 19 fragment as predictive factors for recurrence in patients with stage I non-small cell lung cancer. Lung Cancer. 2007; 58: 369-375. [PubMed:17697728]. (Pubitemid 350051511)
22. Hanagiri T, Sugaya M, Takenaka M, et al. Preoperative CYFRA 21-1 and CEA as prognostic factors in patients with stage I non-small cell lung cancer. Lung Cancer. 2011; 74: 112-117. [PubMed:21397974].
23. Edge SB, Byrd DR, Compton CC, et al. American Joint Committee on Cancer (AJCC) cancer staging manual. 7th ed. Chicago: Springer, Inc, 2010.
24. J.Bruce Smith, David Todd. Foetoglobulin and Primary Liver Cancer. Lancet. 1968; 292: 833.
25. Cooke DT, Nguyen DV, Yang Y, Chen SL, Yu C, Calhoun RF. Survival Comparison of Adenosquamous, Squamous Cell, and Adenocarcinoma of the lung After Lobectomy. Ann Thorac Surg. 2010; 90: 943-948. [PubMed:20732522].
26. Pujol JL, Molinier O, Ebert W, et al. CYFRA 21-1 is a prognostic determinant in non-small-cell lung cancer: results of a meta-analysis in 2063 patients. Br J cancer. 2004; 90: 2097-2105. [PubMed:15150567]. (Pubitemid 38869712)
27. N.I.H. Carcinoembryonic antigen: Its role as a marker in the management of cancer. Br Med J. 1981; 282: 373-375. [PubMed:6780032].